Hereditary spastic paraplegia: pathology, genetics and therapeutic prospects

Roberto Di Fabio, Eugenia Storti, Alessandra Tessa, Francesco Pierelli, Federica Morani, Filippo Maria Santorelli

Research output: Contribution to journalArticle

Abstract

Introduction: The hereditary spastic paraplegias (HSPs), a heterogeneous group of inherited disorders whose main clinical feature is progressive lower limb spasticity, have been reclassified following the cloning of genes associated with familial cases of hypertonic paraparesis. A consequence of the genetic classification of these disorders, based on the type of mutation detected in patients, has been an expansion of the clinical spectrum of the single entities. Paradoxically, this has made the clinical diagnosis of HSPs more complex. Areas covered: Advances in knowledge of HSPs, ranging from clinical aspects to the putative pathophysiological mechanisms, are detailed. Expert opinion: Rapid technological progress in the molecular field, applied to HSPs, has allowed the identification of 84 different disease loci and the cloning of 67 corresponding genes. Updating on recent genetic findings in the HSP field is crucial in order to increase clinician awareness of the additional features of the different forms. Clinical study of patients and their relatives remains the most valuable approach for identifying new cases and tailoring genetic counseling. Future directions in HSP research should address the mechanisms underlying the reduced penetrance of some mutations, and the issue of how novel pathological information can be translated into better care and therapies, given that the latter are currently based largely on symptom relief.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalExpert Opinion on Orphan Drugs
DOIs
Publication statusAccepted/In press - Feb 29 2016

Fingerprint

Hereditary Spastic Paraplegia
Pathology
Organism Cloning
Therapeutics
Paraparesis
Mutation
Inborn Genetic Diseases
Penetrance
Genetic Counseling
Expert Testimony
Genes
Lower Extremity
Research

Keywords

  • corticospinal tracts
  • Hereditary spastic paraplegias
  • HSP
  • spasticity
  • SPG

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Hereditary spastic paraplegia : pathology, genetics and therapeutic prospects. / Di Fabio, Roberto; Storti, Eugenia; Tessa, Alessandra; Pierelli, Francesco; Morani, Federica; Santorelli, Filippo Maria.

In: Expert Opinion on Orphan Drugs, 29.02.2016, p. 1-14.

Research output: Contribution to journalArticle

Di Fabio, Roberto ; Storti, Eugenia ; Tessa, Alessandra ; Pierelli, Francesco ; Morani, Federica ; Santorelli, Filippo Maria. / Hereditary spastic paraplegia : pathology, genetics and therapeutic prospects. In: Expert Opinion on Orphan Drugs. 2016 ; pp. 1-14.
@article{c3f6987c34e74e7da79e0a26c23647a8,
title = "Hereditary spastic paraplegia: pathology, genetics and therapeutic prospects",
abstract = "Introduction: The hereditary spastic paraplegias (HSPs), a heterogeneous group of inherited disorders whose main clinical feature is progressive lower limb spasticity, have been reclassified following the cloning of genes associated with familial cases of hypertonic paraparesis. A consequence of the genetic classification of these disorders, based on the type of mutation detected in patients, has been an expansion of the clinical spectrum of the single entities. Paradoxically, this has made the clinical diagnosis of HSPs more complex. Areas covered: Advances in knowledge of HSPs, ranging from clinical aspects to the putative pathophysiological mechanisms, are detailed. Expert opinion: Rapid technological progress in the molecular field, applied to HSPs, has allowed the identification of 84 different disease loci and the cloning of 67 corresponding genes. Updating on recent genetic findings in the HSP field is crucial in order to increase clinician awareness of the additional features of the different forms. Clinical study of patients and their relatives remains the most valuable approach for identifying new cases and tailoring genetic counseling. Future directions in HSP research should address the mechanisms underlying the reduced penetrance of some mutations, and the issue of how novel pathological information can be translated into better care and therapies, given that the latter are currently based largely on symptom relief.",
keywords = "corticospinal tracts, Hereditary spastic paraplegias, HSP, spasticity, SPG",
author = "{Di Fabio}, Roberto and Eugenia Storti and Alessandra Tessa and Francesco Pierelli and Federica Morani and Santorelli, {Filippo Maria}",
year = "2016",
month = "2",
day = "29",
doi = "10.1517/21678707.2016.1153964",
language = "English",
pages = "1--14",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Hereditary spastic paraplegia

T2 - pathology, genetics and therapeutic prospects

AU - Di Fabio, Roberto

AU - Storti, Eugenia

AU - Tessa, Alessandra

AU - Pierelli, Francesco

AU - Morani, Federica

AU - Santorelli, Filippo Maria

PY - 2016/2/29

Y1 - 2016/2/29

N2 - Introduction: The hereditary spastic paraplegias (HSPs), a heterogeneous group of inherited disorders whose main clinical feature is progressive lower limb spasticity, have been reclassified following the cloning of genes associated with familial cases of hypertonic paraparesis. A consequence of the genetic classification of these disorders, based on the type of mutation detected in patients, has been an expansion of the clinical spectrum of the single entities. Paradoxically, this has made the clinical diagnosis of HSPs more complex. Areas covered: Advances in knowledge of HSPs, ranging from clinical aspects to the putative pathophysiological mechanisms, are detailed. Expert opinion: Rapid technological progress in the molecular field, applied to HSPs, has allowed the identification of 84 different disease loci and the cloning of 67 corresponding genes. Updating on recent genetic findings in the HSP field is crucial in order to increase clinician awareness of the additional features of the different forms. Clinical study of patients and their relatives remains the most valuable approach for identifying new cases and tailoring genetic counseling. Future directions in HSP research should address the mechanisms underlying the reduced penetrance of some mutations, and the issue of how novel pathological information can be translated into better care and therapies, given that the latter are currently based largely on symptom relief.

AB - Introduction: The hereditary spastic paraplegias (HSPs), a heterogeneous group of inherited disorders whose main clinical feature is progressive lower limb spasticity, have been reclassified following the cloning of genes associated with familial cases of hypertonic paraparesis. A consequence of the genetic classification of these disorders, based on the type of mutation detected in patients, has been an expansion of the clinical spectrum of the single entities. Paradoxically, this has made the clinical diagnosis of HSPs more complex. Areas covered: Advances in knowledge of HSPs, ranging from clinical aspects to the putative pathophysiological mechanisms, are detailed. Expert opinion: Rapid technological progress in the molecular field, applied to HSPs, has allowed the identification of 84 different disease loci and the cloning of 67 corresponding genes. Updating on recent genetic findings in the HSP field is crucial in order to increase clinician awareness of the additional features of the different forms. Clinical study of patients and their relatives remains the most valuable approach for identifying new cases and tailoring genetic counseling. Future directions in HSP research should address the mechanisms underlying the reduced penetrance of some mutations, and the issue of how novel pathological information can be translated into better care and therapies, given that the latter are currently based largely on symptom relief.

KW - corticospinal tracts

KW - Hereditary spastic paraplegias

KW - HSP

KW - spasticity

KW - SPG

UR - http://www.scopus.com/inward/record.url?scp=84961216113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961216113&partnerID=8YFLogxK

U2 - 10.1517/21678707.2016.1153964

DO - 10.1517/21678707.2016.1153964

M3 - Article

SP - 1

EP - 14

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

ER -